Axonics generates another $17m
Startup Axonics Modulation Technologies brings in close to $17.3 million in equity funding for its next-generation neuromodulation technology to treat overactive bladder and other conditions.
Axonics Modulation Technologies said it raised nearly $17.3 million in an equity financing as it develops next-generation neuromodulation technology to treat various medical conditions.
The California company disclosed the funding in a recent regulatory filing that does not name specific investors.
Axonics Modulation Technologies, Vessix Vascular Inc.News Well, Funding Roundup, Neuromodulation/Neurostimulationread ...
Source: Mass Device - May 4, 2015 Category: Medical Equipment Authors: Mark Hollmer Source Type: news
Thursday consumer health tips
Lactose Intolerance Barefoot running shoes: Better than traditional running shoes? Fall prevention: Simple tips to prevent falls Overactive bladder Crohn's and ulcerative colitis: What's the difference? (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 30, 2015 Category: Databases & Libraries Source Type: news
Bioness Initiates Pilot Study Of StimRouter Neuromodulation System For Overactive Bladder (OAB)
Bioness, Inc. announced recently that four (4) patients have successfully been implanted with the StimRouter Neuromodulation System, for an ongoing Canadian pilot study to evaluate device use in the treatment of overactive bladder symptoms. (Source: Medical Design Online News)
Source: Medical Design Online News - March 31, 2015 Category: Medical Equipment Source Type: news
Bioness launches clinical trial for StimRouter in overactive bladder
Bioness says 4 patients were successfully implanted with its StimRouter neuromodulation device to treat their overactive bladders.
Bioness last week said it's making progress with a Canadian study of its StimRouter neuromodulation device designed to expand the number of conditions for which it can be used for treatment.
Bioness Inc.News Well, Clinical Trials, Gynecological, Neuromodulation/Neurostimulation, Urologyread more (Source: Mass Device)
Source: Mass Device - March 30, 2015 Category: Medical Equipment Authors: Mark Hollmer Source Type: news
Bioness Initiates Pilot Study of StimRouter(TM) Neuromodulation System for Overactive Bladder (OAB)
VALENCIA, Calif.--(Healthcare Sales & Marketing Network)--Bioness, Inc. announced today that four (4) patients have successfully been implanted with the StimRouter Neuromodulation System, for an ongoing Canadian pilot study to evaluate device use in the tr... Devices, UrologyBioness, StimRouter, Neuromodulation, overactive bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2015 Category: Pharmaceuticals Source Type: news
Overactive Bladder and the Metabolic Syndrome in WomenOveractive Bladder and the Metabolic Syndrome in Women
Could reducing insulin resistance, obesity, and oxidative stress prevent the onset of overactive bladder? This review examined a possible association between metabolic syndrome and OAB in women. International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2015 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
Cigna to cover Uroplasty's over-active bladder treatment
Health insurer Cigna has issued a positive coverage decision on Uroplasty's over-active bladder (OAB) treatment, Percutaneous Tibial Nerve Stimulation (PTNS).
Health insurer Cigna has issued a positive coverage decision on Uroplasty's (NSDQ:UPI) overactive bladder (OAB) treatment, Percutaneous Tibial Nerve Stimulation (PTNS).
Cigna, Uroplasty Inc.News Well, Reimbursementread more (Source: Mass Device)
Source: Mass Device - February 25, 2015 Category: Medical Equipment Authors: Val Kennedy Source Type: news
Overactive bladder treatment: Advanced Uro-solutions bought by Medtronic
Medtronic has snatched up Advanced Uro-solutions, a Tennessee company with an FDA-cleared neurostimulation device to treat overactive bladder.
Medtronic (NYSE:MDT) has wrapped up yet another acquisition, buying Advanced Uro-Solutions, a Tennessee company whose neurostimulation products focus on treating patients with overactive bladder, for an undisclosed amount of money.
Medtronic, Uroplasty Inc.News Well, Mergers & Acquisitionsread more (Source: Mass Device)
Source: Mass Device - February 24, 2015 Category: Medical Equipment Authors: Mark Hollmer Source Type: news
Medtronic buys maker of device for overactive bladders
Medtronic paid an undisclosed amount to acquire Advanced Uro-Solutions, which makes a device that treats overactive bladder.
Elizabethton, Tenn.-based Advanced Uro-Solutions' NURO system technology uses electrical pulses to stimulate nerves that control bladder function. But unlike many Medtronic devices, Advanced Uro-Solutions' system isn't implanted inside the body, and instead uses an external stimulator.
The deal closed in December, Medtronic said Monday. Medtronic plans to launch NURO, which… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - February 23, 2015 Category: Hospital Management Authors: Katharine Grayson Source Type: news
Common anticholinergic drugs like Benadryl linked to increased dementia risk
This study is another reminder to periodically evaluate the all drugs you’re taking. Look at each one to determine if it’s really helping,” says Dr. Sarah Berry, a geriatrician and assistant professor of medicine at Harvard Medical School. “I’ve seen people who have been on anticholinergic medications for bladder control for years and they are completely incontinent. These drugs obviously aren’t helping.”
Many drugs have a stronger effect on older people than younger people. With age, the kidneys and liver clear drugs more slowly, so drug levels in the blood remain higher for a lon...
Source: New Harvard Health Information - January 29, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Alzheimer's Disease Drugs and Supplements Mental Health anticholinergic drugs Source Type: news
Media dementia scare over hay fever and sleep drugs
Conclusion
This large US prospective cohort study suggests a link between those taking high levels of anticholinergic medicines for more than three years and developing dementia in adults over 65.
The main statistically significant finding was in a group taking the equivalent of any of the following medications daily for more than three years:
xybutynin chloride, 5mg
chlorpheniramine maleate, 4mg
olanzapine, 2.5mg
meclizine hydrochloride, 25mg
doxepin hydrochloride, 10mg
These are not unrealistic doses of medicine, so the results may be applicable to a significant proportion of older adults.
Th...
Source: NHS News Feed - January 27, 2015 Category: Consumer Health News Tags: Medication Neurology Source Type: news
How popular hayfever pills 'could raise Alzheimer's risk' by more than 50%
Antihistamines Piriton and Benadryl, sleep remedy Nytol, and Ditropan - to treat an overactive bladder - have all been linked to Alzheimer's, a study by the University of Washington found. (Source: the Mail online | Health)
Source: the Mail online | Health - January 27, 2015 Category: Consumer Health News Source Type: news
Sleep remedies and hayfever pills 'more than DOUBLE the risk of Alzheimer's'
Antihistamines Piriton and Benadryl, sleep remedy Nytol, and Ditropan - to treat an overactive bladder - have all been linked to Alzheimer's, a study by the University of Washington found. (Source: the Mail online | Health)
Source: the Mail online | Health - January 26, 2015 Category: Consumer Health News Source Type: news
Drug Activates Brown Fat and Increases Metabolism
A drug approved to treat overactive bladder can stimulate brown fat and increase energy expenditure in men. The results suggest a strategy for treating obesity and related diseases. (Source: NIH Research Matters)
Source: NIH Research Matters - January 26, 2015 Category: Research Source Type: news
Overactive Bladder a Common Problem, FDA Says
But many people are too embarrassed to seek treatment, or don't know options exist (Source: WebMD Health)
Source: WebMD Health - January 19, 2015 Category: Consumer Health News Source Type: news
